Neurosync

NeuroSync operates at the intersection of digital health, medical devices, sports medicine, and neurorehabilitation. Its differentiation is the combination of a VR or XR headset, eye tracking, proprietary eye-movement analytics, and clinical reporting in a portable workflow for concussion assessment and brain-health evaluation. EYE-SYNC is positioned for healthcare professionals and sports organizations that need objective visual-orientation, gaze-fixation, and smooth-pursuit measurements rather than solely subjective symptom reporting. PRO-SYNC broadens the addressable use case toward wellness, sleep-quality monitoring, and mental-acuity screening, while the NeuroSync Management Portal targets provider administration and care coordination. The company’s stated clinical foundation includes 15 years of research and collaboration involving the U.S. NeuroSync’s 12 granted patents and FDA-cleared flagship product suggest a defensible clinical-technology position, but the $150,000 latest grant and limited disclosed financing make its scale materially less clear than that of larger digital-neurology and concussion-platform companies.

NeuroSync’s trajectory shows a transition from research-led cognitive and visual assessment technology toward a broader digital-health product portfolio. The record identifies the company as founded in 2022, yet it also lists a $3.5 million Series A-1 dated 2018, creating a material chronology conflict that lowers confidence in the historical financing timeline. The most recent financing event is a $150,000 grant on May 12, 2026, which may support product development or commercialization but is not evidence of a large venture expansion. Product breadth is a positive inflection point: EYE-SYNC addresses clinical concussion and brain-health assessment, PRO-SYNC supports mobile screening and monitoring, and the Management Portal handles provider workflows. Intellectual-property activity has continued across multiple years, with a granted patent record dated Oct 29, 2021 and a related publication dated Aug 13, 2024. The company reports an 11–50 employee range and hiring activity in 2021–2022, but no current headcount trend, revenue, customer count, or subsequent institutional financing is disclosed. Overall, the evidence supports ongoing technical development and product diversification, while commercial scale and growth velocity remain difficult to verify.